1790 – POLE genotyping for the molecular classification of endometrial cancer

The Royal College of Pathologists of Australasia

New Medicare Benefits Schedule item.

Genetic testing to detect the presence of POLE mutations in tumour tissue for molecular characterisation of endometrial malignancies. Genetic testing of the POLE gene is used to classify endometrial carcinoma and stratify risk to guide treatment decisions. 

Type: Investigative therapy

Endometrial carcinoma is the 5th most common cancer in females and the most common gynaecological cancer (95% of diagnosed uterine cancers are endometrial cancers, arising from the inner lining of the uterus). Incidence of endometrial carcinoma has increased over time, and although 5-year survival rates are good it is still associated with significant morbidity and mortality.

Provide your input online

The following consultation deadlines apply:

• Pre-PASC consultation deadline: 14 March 2025
• Pre-MSAC consultation deadline: - 

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

This application will be considered at the following meetings:

• PASC meeting: 16 to 17 April 2025
• ESC meeting: -
• MSAC meeting: -

Find out more about our meetings.

The outcome of this application is pending.

Find out more about:

• the MSAC process
• application types
• application timelines.